The podocyte as a target for therapies-new and old

Nature Reviews Nephrology

Volumn 8, Issue 1, 2012, Pages 52-56

  Mathieson, Peter W ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; FENOFIBRATE; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVAMISOLE; LOSARTAN; MIZORIBINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RAPAMYCIN; RHO KINASE INHIBITOR; RITUXIMAB; SIMVASTATIN; SPIRONOLACTONE; TACROLIMUS; TELMISARTAN; TOLVAPTAN; TRIPTOLIDE;

CELL DAMAGE; CELL FUNCTION; CELL TYPE; CYTOSKELETON; DIABETIC NEPHROPATHY; DRUG DESIGN; DRUG TARGETING; GLOMERULOSCLEROSIS; HUMAN; KIDNEY DISEASE; MORBIDITY; NEPHROTIC SYNDROME; NONHUMAN; PLASMAPHERESIS; PODOCYTE; PRIORITY JOURNAL; REVIEW;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; PLASMA EXCHANGE; PODOCYTES;

EID: 84455208254     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2011.171     Document Type: Review

References (59)

1. Patrakka, J. & Tryggvason, K. New insights into the role of podocytes in proteinuria. Nat. Rev. Nephrol. 5, 463-468 (2009).
2. Mathieson, P. W. Update on the podocyte. Curr. Opin. Nephrol. Hypertens. 18, 206-211 (2009).
3. Hlatky, M. A. Is renal biopsy necessary in adults with nephrotic syndrome. Lancet 2, 1264-1268 (1982). (Pubitemid 13240867)
4. Ransom, R. F., Lam, N. G., Hallett, M. A., Atkinson, S. J. & Smoyer, W. E. Glucocorticoids protect and enhance recovery of cultured murine podocytes via actin filament stabilization. Kidney Int. 68, 2473-2483 (2005). (Pubitemid 43250994)
5. Xing, C. Y. et al. Direct effects of dexamethasone on human podocytes. Kidney Int. 70, 1038-1045 (2006).
6. Wada, T., Pippin, J. W., Marshall, C. B., Griffin, S. V. & Shankland, S. J. Dexamethasone prevents podocyte apoptosis induced by puromycin aminonucleoside: role of p53 and Bcl-2-related family proteins. J. Am. Soc. Nephrol. 16, 2615-2625 (2005).
7. Fuji, Y. et al. The effect of dexamethasone on defective nephrin transport caused by ER stress: a potential mechanism for the therapeutic action of glucocorticoids in the acquired glomerular diseases. Kidney Int. 69, 1350-1359 (2006).
8. Guess, A. et al. Dose-and time-dependent glucocorticoid receptor signaling in podocytes. Am. J. Physiol. Renal Physiol. 299, F845-F853 (2010).
9. Ohashi, T., Uchida, K., Uchida, S., Sasaki, S. & Nitta, K. Dexamethasone increases the phosphorylation of nephrin in cultured podocytes. Clin. Exp. Nephrol. doi:10.1007/s10157-011-0479-0.
10. Uchida, K. et al. Decreased tyrosine phosphorylation of nephrin in rat and human nephrosis. Kidney Int. 73, 926-932 (2008). (Pubitemid 351458318)
11. Hussain, S. et al. Nephrin deficiency activates NF-kappaB and promotes glomerular injury. J. Am. Soc. Nephrol. 20, 1733-1743 (2009).
12. Mudge, S. J. et al. Corticosteroids worsen proteinuria and increase intraglomerular signaling by NF-kB in a model of membranous glomerulonephritis. Nephron Exp. Nephrol. 116, e23-e31 (2010).
13. Lindskog, A. et al. Melanocortin 1 receptor agonists reduce proteinuria. J. Am. Soc. Nephrol. 21, 1290-1298 (2010).
14. Faul, C. et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat. Med. 14, 931-938 (2008).
15. Bensman, A. & Niaudet, P. Non-immunologic mechanisms of calcineurin inhibitors, explain its antiproteinuric effects in genetic glomerulopathies. Pediatric Nephrol. 25, 1197-1199 (2010).
16. Torras, J. et al. Rapamycin has dual opposing effects on proteinuric experimental nephropathies: is it a matter of podocyte damage? Nephrol. Dial. Transplant. 24, 3632-3640 (2009).
17. Stallone, G. et al. Sirolimus and proteinuria in renal transplant patients: evidence for a dose-dependent effect on slit diaphragm proteins. Transplantation 91, 997-1004 (2011).
18. Inoki, K. et al. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J. Clin. Invest. 121, 2181-2196 (2011).
19. Gödel, M. et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J. Clin. Invest. 121, 2197-2209 (2011).
20. Mathieson, P. W. Clinical Implications of basic research: proteinuria and immunity-an overstated relationship? N. Engl. J. Med. 359, 2492-2494 (2008).
21. Fornoni, A. et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci. Transl. Med. 3, 85ra46 (2011).
22. Szeto, C. C., Gillespie, K. M. & Mathieson, P. W. Levamisole induces interleukin-18 and shifts type 1/type 2 cytokine balance. Immunology 100, 217-224 (2000). (Pubitemid 30348868)
23. Harris, J. J., Welsh, G. I., Mathieson, P. W. & Saleem, M. A. FSGS plasma initiates specific signalling pathways in podocytes-evidence for an imbalance of circulating proteases abstract TH-PO908. Presented at The American Society of Nephrology Renal Week 2009.
24. Winn, M. P. et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 308, 1801-1804 (2005). (Pubitemid 40848011)
25. Puri, A., McGoon, M. D. & Kushwaha, S. S. Pulmonary arterial hypertension: current therapeutic strategies. Nat. Clin. Pract. Cardiovasc. Med. 4, 319-329 (2007). (Pubitemid 46860549)
26. Komers, R. Rho kinase inhibition in diabetic nephropathy. Curr. Opin. Nephrol. Hypertens. 20, 77-83 (2011).
27. Macconi, D. et al. Podocyte repopulation contributes to regression of glomerular injury induced by ACE inhibition. Am. J. Pathol. 174, 797-807 (2009).
28. Fukuda, A., Fujimoto, S., Iwatsubo, S., Kawachi, H. & Kitamura, K. Effects of mineralocorticoid and angiotensin II receptor blockers on proteinuria and glomerular podocyte protein expression in a model of minimal change nephrotic syndrome. Nephrology (Carlton) 15, 321-326 (2010).
29. Nishiyama, A. et al. Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats. J. Pharmacol. Exp. Ther. 332, 1072-1080 (2010).
30. Lin, S. et al. Spironolactone ameliorates podocytic adhesive capacity via restoring integrin alpha 3 expression in streptozotocin-induced diabetic rats. J. Renin Angiotensin Aldosterone Syst. 11, 149-157 (2010).
31. Okada, T. et al. Tolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats. Clin. Exp. Nephrol. 13, 438-446 (2009).
32. Sakurai, N. et al. Fluvastatin prevents podocyte injury in a murine model of HIV-associated nephropathy. Nephrol. Dial. Transplant. 24, 2378-2383 (2009).
33. Wei, P. et al. Simvastatin reverses podocyte injury but not mesangial expansion in early stage type 2 diabetes mellitus. Ren. Fail. 31, 503-513 (2009).
34. Zhou, Y. et al. Peroxisome proliferator-activated receptor-α is renoprotective in doxorubicin-induced glomerular injury. Kidney Int. 79, 1302-1311 (2011).
35. Eto, N. et al. Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression. Kidney Int. 72, 455-463 (2007). (Pubitemid 47237606)
36. Schiffer, M. et al. Erythropoietin prevents diabetes-induced podocyte damage. Kidney Blood Press. Res. 31, 411-415 (2008).
37. Ruester, C., Franke, S., Bondeva, T. & Wolf, G. Erythropoietin protects podocytes from damage by advanced glycation end-products. Nephron Exp. Nephrol. 117, e21-e30 (2011).
38. Takeuchi, S. et al. The immunosuppressive drug mizoribine directly prevents podocyte injury in puromycin aminonucleoside nephrosis. Nephron Exp. Nephrol. 116, e3-e10 (2010).
39. Chen, Z. H. et al. Triptolide reduces proteinuria in experimental membranous nephropathy and protects against C5b-9-induced podocyte injury in vitro. Kidney Int. 77, 974-988 (2010).
40. Gao, Q. et al. Treatment of db/db diabetic mice with triptolide: a novel therapy for diabetic nephropathy. Nephrol. Dial. Transplant. 25, 3539-3547 (2010).
41. Dai, C., Saleem, M. A., Holzman, L. B., Mathieson, P. & Liu, Y. Hepatocyte growth factor signaling ameliorates podocyte injury and proteinuria. Kidney Int. 77, 962-973 (2010).
42. Kato, T., Mizuno, S. & Nakamura, T. Preservations of nephrin and synaptopodin by recombinant hepatocyte growth factor in podocytes for the attenuations of foot process injury and albuminuria in nephritic mice. Nephrology (Carlton) 16, 310-318 (2011).
43. Satchell, S. C. et al. Interferon-beta reduces proteinuria in experimental glomerulonephritis. J. Am. Soc. Nephrol. 18, 2875-2884 (2007). (Pubitemid 350058394)
44. Kang, Y. S. et al. Inhibition of integrin-linked kinase blocks podocyte epithelial-mesenchymal transition and ameliorates proteinuria. Kidney Int. 78, 363-373 (2010).
45. Ma, H. et al. Inhibition of podocyte FAK protects against proteinuria and foot process effacement. J. Am. Soc. Nephrol. 21, 1145-1156 (2010).
46. Agarwal, R. Are vitamin D receptor agonists like angiotensin-converting enzyme inhibitors without side effects? Kidney Int. 77, 943-945 (2010).
47. Zou, M. S. et al. 1, 25-dihydroxyvitamin D3 decreases adriamycin-induced podocyte apoptosis and loss. Int. J. Med. Sci. 7, 290-299 (2010).
48. Kwak, S. J. et al. Local kallikrein-kinin system is involved in podocyte apoptosis under diabetic conditions. Apoptosis 16, 478-490 (2011).
49. Barutta, F. et al. Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy. Diabetes 59, 1046-1054 (2010).
50. Ahn, S. H. & Susztak, K. Getting a notch closer to understanding diabetic kidney disease. Diabetes 59, 1865-1867 (2010).
51. Welsh, G. I. et al. Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metab. 12, 329-340 (2010).
52. Piwkowska, A. et al. Metformin induces suppression of NAD(P)H oxidase activity in podocytes. Biochem. Biophys. Res. Commun. 393, 268-273 (2010).
53. Liu, H. F. et al. Thiazolidinedione attenuate proteinuria and glomerulosclerosis in Adriamycin-induced nephropathy rats via slit diaphragm protection. Nephrology (Carlton) 15, 75-83 (2010).
54. Mironidou-Tzouveleki, M., Tsartsalis, S. & Tomos, C. Vascular endothelial growth factor (VEGF) in the pathogenesis of diabetic nephropathy of type 1 diabetes mellitus. Curr. Drug Targets. 12, 107-114 (2011).
55. Saito, D. et al. Amelioration of renal alterations in obese type 2 diabetic mice by vasohibin-1, a negative feedback regulator of angiogenesis. Am. J. Physiol. Renal Physiol. 300, F873-F886 (2011).
56. Appel, D. et al. Recruitment of podocytes from glomerular parietal epithelial cells. J. Am. Soc. Nephrol. 20, 333-343 (2009).
57. Roufosse, C. & Cook, H. T. Stem cells and renal regeneration. Nephron Exp. Nephrol. 109, e39-e45 (2008).
58. Becker, J. U., Hoerning, A., Schmid, K. W. & Hoyer, P. F. Immigrating progenitor cells contribute to human podocyte turnover. Kidney Int. 72, 1468-1473 (2007). (Pubitemid 350197943)
59. Lasagni, L. & Romagnani, P. Glomerular epithelial stem cells: the good, the bad, and the ugly. J. Am. Soc. Nephrol. 21, 1612-1619 (2010).